Roivant Sciences (ROIV) Financial Analysis & Valuation | Quarter Chart
Roivant Sciences (ROIV)
ROIVPrice: $34.01
Fair Value: 🔒
🔒score
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, a... more
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and dev... more
Description
Shares
| Market Cap | $24.46B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | GB | CEO | Matthew Gline |
| IPO Date | 2020-12-08 | CAGR | -0.3% |
| Employees | 908 | Website | roivant.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 1.49% | Total Yield | 1.49% |
ROIV chart loading...
Fundamentals
Technicals
| Enterprise Value | $21.05B | P/E Ratio | -37.74 |
| Forward P/E | -21.81 | PEG Ratio | — |
| P/S Ratio | 2584.44 | P/B Ratio | 4.61 |
| P/CF Ratio | -27.79 | P/FCF Ratio | -28.14 |
| EPS | $-0.9 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -71.57% | Gross Margin | 0.84% |
| Operating Margin | -155.61% | Profit Margin | -36.29% |
| ROE | -0.07% | ROA | -0.05% |
| ROCE | -0.24% | Current Ratio | 18.37 |
| Quick Ratio | 18.37 | Cash Ratio | 5.06 |
| Debt/Equity | 0.02 | Interest Coverage | — |
| Altman Z Score | 33.85 | Piotroski Score | 1 |